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https://doi.org/10.1016/j.ajic.2019.01.017Millions of gastrointestinal endoscopes are performed each year in the United States. Gastrointestinal endo-
scopes become highly contaminated during use (ie, internal channels contain 7-10-log10 enteric microorgan-
isms). Currently, endoscopes (eg, bronchoscopes and gastrointestinal endoscopes) are classified as
semicritical items because they contact intact mucous membranes and most commonly undergo cleaning
followed by high-level disinfection, which may result in as little as a 6-log10 reduction of microorganisms.
Therefore, and not surprisingly, in recent years there have been multiple reports that have documented that
endoscopes, especially duodenoscopes, frequently remain contaminated with bacterial pathogens after
proper cleaning and disinfection. Multiple outbreaks of multidrug-resistant organisms from contaminated
duodenoscopes have resulted in substantial death and morbidity. Because duodenoscopes commonly contact
nonintact mucous membranes and sterile tissue, such endoscopes should be considered critical items. We
propose that to ensure patient safety, we follow the Spaulding scheme and move from high-level disinfection
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vanced Sterilization Products.For more than a century, the founders of Mayo Clinic instilled “the
needs of the patient come first” into the culture of the institution. The
profound allegiance of Mayo Clinic to its patient-centered culture
connects all staff to the purpose of their work and promotes an
environment that is committed to excellence and continuous
improvement.1 The purpose of this article is to consider this primary
value, in the context of the contemporary challenge of endoscope
reprocessing, and how to provide the best care to the 18 million
patients who receive an endoscopic procedure each year in the
United States through improved cleaning and a shift from disinfection
to sterilization.2-5
During the past few years, there have been >25 outbreaks of mul-
tidrug-resistant organisms (MDROs) (such as carbapenem-resistantEnterobacteriaceae [CRE]) in major hospitals in the United States and
in the world that have killed dozens of patients and caused morbidity
in hundreds more.6,7 These outbreaks have been linked primarily to
contaminated duodenoscopes that are used to diagnose and treat dis-
ease of the liver, bile ducts, and pancreas.6,7 Gastrointestinal (GI)
endoscopes (eg, colonoscopes, gastroscopes, and duodenoscopes)
and bronchoscopes have been associated with >130 outbreaks caus-
ing more death and illness.6,8 Although GI endoscopes and broncho-
scopes have contact with intact mucous membranes, but frequently
have contact with nonintact mucous membranes and sterile tissue
(via a biopsy or entrance into normally sterile areas such as bile ducts,
lung, etc), there is a risk of patient-to-patient transmission of poten-
tial pathogens with a subsequent risk of infection.6,8-10
The key concern raised by these outbreaks is whether current
reprocessing guidelines for endoscopes are adequate to ensure a
patient-safe endoscope (ie, 1 devoid of potential pathogens) or if
endoscopes, with their long, narrow channels, right-angle turns, diffi-
cult-to-clean and disinfect components, heavy microbial contamina-
tion, and presence of biofilm, make it impossible to achieve
high-level disinfection (HLD). To examine this concern and to offer
recommendations, understanding the current knowledge on endo-
scope reprocessing is necessary.
First, endoscopes have been considered semicritical devices because
they have contact with intact mucous membranes and require at least
HLD. It is noteworthy that in the Spaulding scheme,11 which identifies
how an object should be disinfected or sterilized, it states that mucous
membranes should be intact and that sterilization of semicritical items
is desirable. HLD is supposed to achieve complete elimination of all
microorganisms, except for small numbers of bacterial spores. How-
ever, the data demonstrated that 30% or more reprocessed endoscopes
are contaminated with substantial numbers of potential pathogens.12
Additionally, the data demonstrated that when screening and/or sur-
veillance colonoscopy was performed on 1,580,318 patients, a biopsy
intervention, which resulted in the penetration of a mucous mem-
brane, occurred in 59.2% of cases. Therefore, in approximately 60%
of screening colonoscopies, there is a high likelihood of contact with
sterile tissue (ie, underlying tissue and blood).9 Based on the Spaulding
classification scheme, the colonoscope that has contact with nonintact
mucous membranes would be a “critical” item requiring sterilization.11
The duodenoscope, cystoscope, and bronchoscope would also be
considered “critical,” as they indirectly contact normally sterile tissue
such as bile ducts, the bladder, and the lung, respectively.11 Because
flexible GI endoscopic and bronchoscopic instruments are heat labile,
only HLD with chemical agents or low-temperature sterilization tech-
nologies (LTSTs) are possible.13,14 Until recently, there were no LTSTs
cleared for GI endoscopes using the Food and Drug Administration
(FDA) guidance document.15 However, currently there are 2 FDA-
cleared LTSTs (Anderson Products, Haw River, NC and TSO3, Quebec,
Canada).
Second, endoscopes have been associated with far more outbreaks
of infections (>130 outbreaks) than any other reusable medical or
surgical device in health care.6-8 In the past, these outbreaks have
been commonly traced to deficient practices such as inadequate
cleaning, inappropriate disinfection, and damaged endoscopes or
flaws in the design of the endoscope or automated endoscope reproc-
essor (AER).8 However, in the past few years there have been at least
9 outbreaks of duodenoscope-related infections of MDROs without
reprocessing breaches.16-24 The Centers for Disease Control and Pre-
vention and/or other investigators monitored endoscope-reprocess-
ing procedures used in these outbreaks and concluded that the
institutions were compliant with the manufacturer’s instructions for
use and professional organizational recommendations.16-24
Rubin et al7 identified 32 outbreaks involving duodenoscopes
with almost 400 patients between January 2000 and December 2017.
There were 9 published outbreaks in which there were no identified
breaches in endoscope reprocessing (Table 1).16-24 In the patientsTable 1






Klebsiella pneumoniae mcr-1 2 No
K pneumoniae blaoxa-232 15 (8) No
Escherichia coli (AmpC) blaCMY-2 35 No
K pneumoniae blaoxa-48 12 Yes
K pneumoniae blaKPC 34? No
E coli blaNDM 39 Yes
Pseudomonas aeruginosa blaVIM-2 22 Yes
E coli blaNDM-1 3 (3) No
K pneumoniae blaKPC-2, blaSHV-12 13 Yes
CRE, carbapenem-resistant Enterobacteriaceae; MDRO, multidrug-resistant organism; MLS
gel electrophoresis; WGS, whole-genome sequencing.
*PCR for resistance gene.who had undergone endoscopic retrograde cholangiopancreatogra-
phy (ERCP) procedures, a clonal strain of the MDRO (eg, CRE) was
identified, and there was a molecular link between a positive scope
and the patient isolate. The number of patients infected in the out-
breaks varied from 2-39 persons, and in several outbreaks there was
propagated spread to patients who had not undergone endoscopy. At
least on 1 occasion when the manufacturer evaluated the contami-
nated scope, the scope had 1 or more critical defects requiring a
repair that had not been detected by the facility.16 Transmission was
attributed to design flaws, which prevented effective cleaning and
allowed persistent contamination at the elevator region.6,25 CRE and
other MDROs are susceptible to disinfectants, and it is lack of expo-
sure on the microbial contaminants that impeded effective inactiva-
tion.26-28 Based on these and other studies,6,7 it is likely that MDROs
are acting as an “indicator” or “red-flag” organisms for ineffective
reprocessing of the complex design of duodenoscopes, which are an
infectious risk to patients. In addition to outbreaks, reprocessing fail-
ures (especially of endoscopes) have led to patient notifications and
bloodborne pathogen testing in tens of thousands of patients.29 To
mitigate this risk, most endoscopy centers have implemented
enhanced duodenoscope-reprocessing techniques (eg, 63% of 249
surveyed endoscopy centers repeated HLD).30 Unfortunately, a ran-
domly assigned trial of single versus double HLD of duodenoscopes
and linear echoendoscopes showed that double HLD did not reduce
culture positivity rates, compared with single HLD, and the elevator
mechanism was colonized more frequently than the channel sam-
ples.31 This finding suggests that there may be internal bacterial con-
tamination of the duodenoscope in areas (eg, elevator mechanism)
that are not adequately exposed to brushes, detergents, and/or disin-
fectants and therefore not addressed through a second HLD.25
Third, evidence-based endoscope-reprocessing guidelines have
been prepared by professional organizations (eg, Society of Gas-
troenterology Nurses and American Society of Gastrointestinal
Endoscopists)32-34 and the Centers for Disease Control and Pre-
vention.14 Unfortunately, there are also data that demonstrate
that all of the steps associated with manual endoscope reprocess-
ing are rarely performed (1.4% compliance rate) and some essen-
tial steps (eg, brushing all endoscope channels and components)
are commonly not performed.35 Endoscope reprocessing was
improved with the use of AERs because most steps were auto-
mated and standardized.35
Fourth, recent microbial surveillance of GI endoscopes demon-
strates GI endoscope contamination rates (>100 colony forming units
[CFU]/endoscope) of 30% or greater, and high contamination rates
were associated with endoscopes older than 2 years and not stored in
storage cabinets.12 Recently, investigators found all endoscopes
(n = 20) had visible irregularities as well as fluid discoloration (95%)ches
Positive scope(s) Molecular link Reference
No Yes-WGS Shenoy et al, 201821
No Yes-PCR Kim et al, 201619
Yes (2) Yes-PCR, PFGE Wendorf et al, 201516
No Yes-PCR, PFGE Kola et al, 201523
Yes (3) Yes-PCR, PFGE, MLST, WGS Marsh et al, 201522
Yes (1) Yes-PCR, PFGE Epstein et al, 201417
Yes (1) Yes-PCR*, PFGE, repetitive-
sequence-based PCR typing
Verfaillie et al, 201524
No Unknown Smith et al, 201520
Yes (2) Yes-PCR, PFGE, MLST Carbonne et al, 201018
T, multilocus sequence typing; PCR, polymerase chain reaction; PFGE, pulsed-field
and debris in the channels.36 Microorganisms can reside in scratches,
grooves, and irregular surfaces and are likely to be protected from
disinfectant exposure.37,38 Further, residual microorganisms can lead
to biofilm formation, which further degrades the effectiveness of dis-
infection.
Fifth, endemic transmission of infections associated with GI endo-
scopes may go unrecognized owing to inadequate or complete lack of
surveillance of outpatient procedures, the long lag time between col-
onization and infection, and a low frequency of infection. Therefore,
it is likely that we are seeing only a very small subset of the coloniza-
tions and/or infections from these endoscopes, as transfer of some
normal enteric microflora (eg, Escherichia coli, Enterococcus) may not
be pathogenic, or immediately pathogenic, and may therefore go
unnoticed. In the outbreaks studied by Epstein et al17 and Wendorf et
al,18 it was the presence of an unusual pathogen (eg, New Delhi met-
allo-b-lactamase-producing E coli) that resulted in an investigation
and recognition that duodenoscopes were the source of the outbreak.
Additionally, the risk for some procedures might be lower than other
procedures in which normally sterile areas are contaminated (eg,
colonoscopy vs ERCP). Furthermore, the risk is likely increased owing
to the increasing use of these procedures (eg, ERCPs and bronchos-
copies) in patients with advanced age, cancers, organ transplantation,
severe underlying disease, and other host defense abnormalities or
immunocompromising diseases or medications.
Last, the margin of safety associated with reprocessing endo-
scopes is nonexistent or <0 (ie, risk is >0). Endoscopes are heavily
contaminated with microbes because they enter the GI tract with its
very high microbial load (eg, microbial load in the colon is 109-12 [9-
12-log10]/mL). Studies have shown that the internal channel of GI
endoscopes may contain 7-10-log10 enteric microorganisms.39-43
Investigations have demonstrated that the cleaning step in endo-
scope reprocessing results in a 2-6-log10 reduction of microbes and
the HLD step results in another 4-6-log10 reduction of mycobacteria
for a total 6-12-log10 reduction of microbes (ie, sum of reduction
from cleaning and HLD).39-43 Therefore, the margin of safety associ-
ated with cleaning and HLD of GI endoscopes is nonexistent or <0
(level of contamination after reprocessing can be 10,000 microbes;
the calculation considers maximal contamination [10-log10] and min-
imal cleaning/HLD [6-log10]).3-5 This nonexistent margin of safety
associated with endoscope reprocessing compares to the 17-log10
margin of safety associated with cleaning and sterilization of surgical
instruments.3-5
If the margin of safety for endoscope reprocessing is so small that
perfect compliance with >100 pages of the manufacturer’s instruc-
tions for use is required, then the endoscope design is too complex,
the microbial load is too high, and the process is too unforgiving to be
practical in the real world. Therefore, what must be done to ensure
“the needs of the patient come first” and these commonly used devices
are reliably devoid of microbial contamination? There are 3 essential
components. First, endoscopy is an important diagnostic and thera-
peutic modality and should continue to be used while clinicians
strictly enforce evidence-based practices, which rely on objective sci-
entific data and are essentially insulated from human bias.14,32-34
These practices include proper equipment maintenance (eg, mini-
mally annually), routine audits (and follow-up of deficiencies), ade-
quate drying of endoscope channels via drying cabinets (scope dry
within 3 hours), consistent and standardized reprocessing among
medical facilities, and the need for thorough training of reprocessing
staff, with at least initial and yearly competency testing (including
training on new instruments and new reprocessing steps such as a
new brush [MAJ-1888] for Olympus duodenoscopes (Olympus Corp.,
Center Valley, PA) or positioning the elevator lever at 45o when a
duodenoscope is placed in an AER).44 Moisture remaining in the
channels after inadequate drying may contribute to the development
of a biofilm.36 In addition, we must understand what facilitates theformation of biofilms (eg, incomplete drying)45 and the role of bio-
films as a source of pathogens.46 Tolerance of bacteria in biofilms to
high-level disinfectants (eg, peracetic acid) has been demonstrated47
and might contribute to disinfection failure of endoscope reprocess-
ing if biofilms build-up in the endoscope channels.48 Inspection of
endoscope channels after reprocessing using a borescope has been
used by some endoscopy centers to audit reprocessing performance
and to identify moisture, debris, discoloration, scratches, and
biofilm.49
Second, real-time monitoring methods need to be developed and
validated to assess the effectiveness of cleaning and be predictive of
microbial contamination. Cleaning must consistently and reliably
remove and/or reduce the organic and inorganic materials so as not
to interfere with the effectiveness of HLD or sterilization.50 Current
cleaning assessment tools (eg, visual, adenosine triphosphate [ATP])
are primitive and not predictive of microbial contamination51 or
infection risks. Detection of ATP, a molecule found in and around liv-
ing cells, has been used to assess the cleanliness of surfaces and devi-
ces. A validation study of ATP used to audit cleaning of flexible
endoscope channels used a benchmark for clean of <200 relative light
units, which equated to <4-log10 CFU/cm2 (or 104 CFUs/cm2)52 or
about 106 CFU per endoscope as the surface area of an endoscope
channel exceeds 100 cm2. Thus, an endoscope assessed as clean by
ATP could still have a substantial microbial load (eg, 106) and ATP
correlates poorly with terminal culture results.53 Other cleaning
verification measures that have been used include protein, total
organic carbon, carbohydrate, hemoglobin, bilirubin, and detecting
enzymes specific to gram-negative bacteria.40,54 Preferably, cleaning
verification tests would directly monitor or be predictive of microbial
contamination. Some health care facilities have implemented a sys-
tematic microbiologic sampling program to monitor the efficacy of
endoscope reprocessing.55 Cleaning should consistently reduce the
microbial load by at least 6-8-log10. This should be accomplished by
the use of AERs, new cleaning methods (eg, pull-through cleaners;56
NanoCleaning Technology, NovaFlux Technologies, Princeton, NJ) and
new chemistries. Ideally, new cleaning and/or antimicrobial chemis-
tries will have biofilm-inhibiting or destruction properties. Improved
automated cleaning and drying may prevent the development of
intractable biofilm that cannot be eradicated by standard reprocess-
ing practices. Automated cleaning technologies that clean the inside
and outside on endoscopes beyond the Association for the Advance-
ment of Medical Instrumentation standards and more effectively
than certified technicians must be developed and used.
Third, to provide a margin of safety we must transition from disin-
fection to sterilization. Because sterilization results in a 12-log10
reduction of spores (ie, 1 trillion spores) and HLD results in a 6-log10
reduction (ie, 1 million microorganisms, not spores), sterilization will
provide a safety margin (approximately 6-log10). Improvements in
cleaning, although essential, without transition to sterilization will
not provide an essential margin of safety. This transition from disin-
fection to sterilization could be accomplished by a clarification of the
Spaulding definition of critical items from “objects that enter sterile
tissue or the vascular system or through which blood flows should be
sterile” to “objects that directly or indirectly (ie, via a mucous mem-
brane such as duodenoscope) enter normally sterile tissue or the
vascular system or through which blood flows should be sterile.”
This clarification would minimally require instruments that enter a
mucous membrane but indirectly contact normally sterile tissue be
classified as critical (eg, cystoscope [bladder], bronchoscope [lung],
and duodenoscope [duodenum, bile ducts]). Other GI scopes, such as
colonoscopes, commonly disrupt mucous membranes and would be
interpreted by the revised Spaulding scheme as also being “critical”
and requiring sterilization.3-5,11 Implementation of this recommenda-
tion requires sterilization technologies that achieve a sterility assur-
ance level of 6-log10 using real-world testing methods (eg, spore
Table 2
Potential future sterilization methods for endoscopes and a proposed method for transitioning from disinfection to sterilization
Potential future sterilization methods or alternative methods
 Optimize current low-temperature sterilization methods or new LTST proving SAL 10¡6 achieved.
 Disposable sterile GI endoscopes/bronchoscopes. A disposable endoscope costs from $170 (bronchoscope) to an estimated $225 (GI endoscope), whereas reprocessing
HLD costs are $114-$281.58
 Steam sterilization for GI and other endoscopes.
 Use of nonendoscope methods to diagnosis or treat disease (eg, capsule endoscopy, stool or blood tests to detect GI cancer, and stool DNA test).
 Improved GI endoscope design (to reduce or eliminate reprocessing challenges; however, based on 50 years of experience, design changes are unlikely to resolve the
endoscope-reprocessing problem [eg, the closed-channel duodenoscopes increased the infection risk]).
Proposed method for transitioning from disinfection to sterilization
 Professional and consensus standard organizations (eg, SHEA, APIC, SGNA, ASGE, and AAMI) should clarify the Spaulding classification scheme for critical items from
“direct contact with sterile tissue” to “direct or indirect contact with sterile tissue.”
 These organizations should incorporate this new clarification into the HLD and sterilization standards, guidelines, and guidance documents.
 These organizations should incorporate verbiage that this transition should happen as soon as new sterilization technology (or single-use endoscopes) is acceptable in
terms of sterilization performance, scope performance (disposable), cost, throughput, and materials compatibility with the sterilization process.
 TJC, CMS, and other accrediting agencies should ensure implementation of these guidelines and consensus standards as soon as new sterilization technologies are
available and acceptable (based on literature and hospital usage).
 Endoscope manufacturers must make their endoscopes compatible with LTST (eg, adhesives and lubricants [such as molybdenum disulfide]). The FDA must ensure
endoscope manufacturers facilitate compatibility with LTST.
 The FDA must clear in a timely manner LTST or single-use/disposable endoscopes when data demonstrate they achieve an SAL 10¡6. Validation tests of LTST must be
robust and reflect worst-case conditions (eg, high spore load, clinical fluids, organic matter, manual cleaning, and used endoscopes [not new endoscopes]), and the FDA
should mandate clinical-use studies. Validation tests with a LTST using a few replicates (eg, 5 replicates), low inoculum (eg, 106), new scopes or surrogate models, and/or
no organic soil do not represent real-world conditions. LTST that have not been cleared by the FDA to achieve an SAL of 10¡6 using the FDA-guidance document
(or preferably a more challenging method than the FDA-guidance document) are not likely to reliably result in sterilization of endoscopes.59
 To protect the public health and to prevent endoscope-related infections and outbreaks, the FDA should mandate a shift from HLD to sterilization, as they did in 1992 with
dental handpieces.
Manufacturers that submit critical devices to the FDA for clearance that directly/indirectly enter normally sterile tissue need to offer an FDA-cleared sterilization method.
 Professional organizations must facilitate this change via guidelines, research, education, and presentations at professional meetings.
AAMI, Association for the Advancement of Medical Instrumentation; APIC, Association for Professionals in Infection Control and Epidemiology; ASGE, American Society for
Gastrointestinal Endoscopists; CMS, Centers for Medicare and Medicaid Services; FDA, Food and Drug Administration; GI, gastrointestinal; HLD, high-level disinfection; LTST,
low-temperature sterilization technologies; SAL, sterility assurance level; SGNA, Society of Gastrointestinal Nurses and Associates; SHEA, Society of Healthcare Epidemiology of
America; TJC, The Joint Commission.load, clinical fluids, and used [not new] endoscopes) of complex med-
ical instruments such as duodenoscopes.15
This shift to sterilization is likely tooccurby1of 5 technologies:new
or optimized LTSTs,16,17,57 disposable sterile endoscopes (Ambu Inc.,
Columbia, MD), steam sterilization for GI endoscopes, use of nonendo-
scopic methods (eg, capsular endoscopy, stool or blood test to detect
cancer), and possibly an improved design (Table 2). Manufacturers are
meeting the demand for sterilization as there are now 2 sterilization
technologies that are FDA-cleared for endoscopes,16,17 1 disposable
sterile GI endoscope manufacturer, 1 disposable sterile bronchoscope
manufacturer (Ambu Inc., Columbia, MD), and 1 manufacturer of an
autoclavableflexible bronchoscope (OlympusCorp., CenterValley, PA).
A proposed method on how to facilitate this shift from disinfection
to sterilization of endoscopes with the cooperation of standards and
professional organizations, the FDA), and accrediting agencies is
shown in Table 2. The FDA mandated a similar shift from disinfection
to sterilization for dental handpieces in 1992. This mandate occurred
although there were no documented cases of disease transmission
associated with dental handpieces.
Unlike dental handpieces, the infection data are overwhelming
and irrefutable, and the need is urgent. Based on the infection data
and risks, the transition to sterilization of duodenoscopes was recom-
mended by an FDA panel in May 2015. Now, professional organiza-
tions (eg, Society of Healthcare Epidemiology of America, Society of
Gastroenterology Nurses and Associates, and American Society of
Gastrointestinal Endoscopy) and a consensus standards organization
(eg, Association for the Advancement of Medical Instrumentation)
must clarify the term “critical,” as stated earlier, which would facili-
tate the transition from disinfection to sterilization for endoscopes.
Technologies to allow this change to occur are being developed16,17
and FDA-cleared and should be used when acceptable in terms of
sterilization performance, scope performance (for disposable scopes),
cost, throughput, and compatibility of materials (eg, adhesives) to
sterilization technology. Device and sterilization manufacturers,regulatory agencies, GI physicians, inpatient and outpatient endo-
scope-reprocessing centers as well as professional organizations
must reach a general agreement regarding the need for sterilization
and the willingness to replace existing disinfection technologies. This
transition will occur when we put “the needs of the patient first” and
offer every patient an endoscope that is sterile and, therefore, devoid
of potential pathogens.
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